NasdaqCM - Nasdaq Real Time Price • USD
Brainstorm Cell Therapeutics Inc. (BCLI)
As of 12:55 PM EDT. Market Open.
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Sep 2023) | Next Qtr. (Dec 2023) | Current Year (2023) | Next Year (2024) |
---|---|---|---|---|
No. of Analysts | -- | -- | 1 | 1 |
Avg. Estimate | 0 | 0 | -0.7 | -0.28 |
Low Estimate | 0 | 0 | -0.7 | -0.28 |
High Estimate | 0 | 0 | -0.7 | -0.28 |
Year Ago EPS | -0.19 | -0.13 | -0.66 | -0.7 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Sep 2023) | Next Qtr. (Dec 2023) | Current Year (2023) | Next Year (2024) |
---|---|---|---|---|
No. of Analysts | 1 | 1 | 1 | 1 |
Avg. Estimate | -- | -- | -- | -- |
Low Estimate | -- | -- | -- | -- |
High Estimate | -- | -- | -- | -- |
Year Ago Sales | -- | -- | -- | -- |
Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
CURRENCY IN USD | 9/30/2022 | 12/31/2022 | 3/31/2023 | 6/30/2023 |
---|---|---|---|---|
EPS Est. | -0.18 | -0.14 | -0.16 | -0.15 |
EPS Actual | -0.19 | -0.13 | -0.14 | -0.27 |
Difference | -0.01 | 0.01 | 0.02 | -0.12 |
Surprise % | -5.60% | 7.10% | 12.50% | -80.00% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Sep 2023) | Next Qtr. (Dec 2023) | Current Year (2023) | Next Year (2024) |
---|---|---|---|---|
Current Estimate | 0 | 0 | -0.7 | -0.28 |
7 Days Ago | -0.14 | -0.15 | -0.7 | -0.28 |
30 Days Ago | -0.14 | -0.15 | -0.7 | -0.28 |
60 Days Ago | -0.14 | -0.15 | -0.7 | -0.47 |
90 Days Ago | -0.14 | -0.15 | -0.7 | -0.47 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Sep 2023) | Next Qtr. (Dec 2023) | Current Year (2023) | Next Year (2024) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | BCLI | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | -- | -- | -- | 8.30% |
Next Qtr. | -- | -- | -- | 11.90% |
Current Year | -6.10% | -- | -- | 5.60% |
Next Year | 60.00% | -- | -- | 13.00% |
Next 5 Years (per annum) | -- | -- | -- | 11.05% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Downgrade | Maxim Group: Buy to Hold | 9/28/2023 |
Maintains | Maxim Group: Buy | 3/31/2023 |
Upgrade | Maxim Group: Hold to Buy | 2/5/2021 |
Initiated | HC Wainwright & Co.: Buy | 5/15/2018 |
Maintains | Maxim Group: Buy | 8/17/2017 |
Related Tickers
BLRX BioLineRx Ltd.
0.6374
+1.80%
RVPH Reviva Pharmaceuticals Holdings, Inc.
1.7250
+1.47%
GALT Galectin Therapeutics Inc.
2.9300
-4.89%
IMNN Imunon, Inc.
1.3099
-11.49%
SLS SELLAS Life Sciences Group, Inc.
1.3350
-2.56%
ADIL Adial Pharmaceuticals, Inc.
1.3900
-3.81%
GYRE Gyre Therapeutics, Inc.
15.92
+1.05%
TNXP Tonix Pharmaceuticals Holding Corp.
0.1745
+1.99%
ENSC Ensysce Biosciences, Inc.
0.5686
-3.13%
CDTX Cidara Therapeutics, Inc.
13.16
+3.58%